Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by S. Ueha
Robust Antitumor Effects of Combined Anti-Cd4-Depleting Antibody and Anti-Pd-1/Pd-L1 Immune Checkpoint Antibody Treatment in Mice
Cancer immunology research
Cancer Research
Immunology
Secondary Lymphoid Tissue Chemokine (SLC/CCL21)/CCR7 Signaling Regulates Fibrocytes in Renal Fibrosis
Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
Related publications
Rationale of Combination of Anti-Pd-1/Pd-L1 Antibody Therapy and Radiotherapy for Cancer Treatment
International Journal of Clinical Oncology
Medicine
Surgery
Oncology
Hematology
The Safety and Tolerability of Combined Immune Checkpoint Inhibitors (Anti-Pd-1/Pd-L1 Plus Anti-Ctla-4): A Systematic Review and Meta-Analysis
BMC Cancer
Cancer Research
Oncology
Genetics
Immuno-Pet Imaging of 89Zr Labeled Anti-Pd-L1 Domain Antibody
Poor Outcome With Anti-Programmed Death-Ligand 1 (PD-L1) Antibody Due to Poor Pharmacokinetic Properties in PD-1/PD-L1 Blockade-Sensitive Mouse Models
Journal for ImmunoTherapy of Cancer
Oncology
Molecular Medicine
Pharmacology
Cancer Research
Allergy
Immunology
The Efficacy and Safety of Anti-Pd-1/Pd-L1 Antibodies Combined With Chemotherapy or CTLA4 Antibody as a First-Line Treatment for Advanced Lung Cancer
International Journal of Cancer
Cancer Research
Oncology
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Breast Care
Surgery
Oncology
Erratum: The Efficacy and Safety of Anti‐PD‐1/Pd‐l1 Antibodies Combined With Chemotherapy or CTLA4 Antibody as a First‐line Treatment for Advanced Lung Cancer
International Journal of Cancer
Cancer Research
Oncology
The Role of PD-1/PD-L1 Signaling Pathway in Antitumor Immune Response
Klinicka Onkologie
Oncology
Combined Effect of Anti-Pd-L1 Antibody With Low Molecular Weight Compound in the Tumor-Bearing Mouse Model
Proceedings for Annual Meeting of The Japanese Pharmacological Society
